Reusser P
Department of Medicine, University Hospital, Basel, Switzerland.
Support Care Cancer. 1998 Jan;6(1):39-45. doi: 10.1007/s005200050130.
Patients with acute leukemia treated with intensive chemotherapy and recipients of bone marrow or peripheral blood stem cell transplants are at high risk of serious viral disease. Recent progress in diagnostic methods and in antiviral drug treatment has permitted the development of efficient management strategies particularly for infections due to herpes simplex virus, varicella-zoster virus, and cytomegalovirus in these patients. By contrast, specific treatment of other virus infections in immunocompromised cancer patients remains an unresolved issue. The emergence of herpesvirus resistance to antiviral drugs is a matter of concern, and its clinical importance among patients with malignancy needs to be elucidated. Future investigations may furthermore help to clarify the role of novel antiviral agents, such as cidofovir, lobucavir, and compound 1263W94, and of the adoptive immunotherapy with virus-specific CTL clones in severely immunodeficient cancer patients.
接受强化化疗的急性白血病患者以及骨髓或外周血干细胞移植受者,发生严重病毒病的风险很高。诊断方法和抗病毒药物治疗方面的最新进展,已使高效管理策略得以制定,特别是针对这些患者中由单纯疱疹病毒、水痘-带状疱疹病毒和巨细胞病毒引起的感染。相比之下,免疫功能低下的癌症患者中其他病毒感染的特异性治疗仍是一个未解决的问题。疱疹病毒对抗病毒药物产生耐药性的出现令人担忧,其在恶性肿瘤患者中的临床重要性有待阐明。未来的研究可能还会有助于明确新型抗病毒药物(如西多福韦、洛布卡韦和化合物1263W94)以及用病毒特异性CTL克隆进行的过继免疫疗法在严重免疫缺陷癌症患者中的作用。